Denver-based EvoEndo’s offering now covers neonates to adults, expanding the previous indication for patients aged five and older.

The company says its system has been the only option available for sedation-free transnasal endoscopy for pediatric patients above five since 2022. Now, FDA clearance makes safe, transoral endoscopy available to infants and young children.

EvoEndo says the new indication establishes it as “the leading choice for all endoscopies.” The company now offers endoscopy ranging from sedated transoral procedures in babies to sedation-free transnasal cases in adults. Its ChannelMax technology accommodates most standard pediatric accessories, according to a news release. The system has scopes available in both 85 and 110 cm lengths. This makes them suitable for small or challenging anatomy in a broad range of indications.